Literature DB >> 25985746

Status and Prospects of Aptamers as Drug Components.

Christopher M C Mattice1, Maria C DeRosa.   

Abstract

The unique properties of nucleic acid aptamers and their suitability to therapeutic applications have attracted the attention of researchers for more than 2 decades. Aptamers exhibit significant advantages relative to antibody-based therapeutics and can serve dual roles as either the therapeutic agent itself or a targeting modality. Despite this intense research interest, aptamers have been slow to reach the clinic, partly due to practical limitations that can be overcome by rational chemical modifications and ingenious aptamer selection approaches. This review highlights the latest efforts to use aptamers in therapeutic applications, the key properties of aptamers that can be exploited, the aptamers that are currently in clinical trials, as well as speculation on the future of aptamers in the field of nanomedicine.

Mesh:

Substances:

Year:  2015        PMID: 25985746     DOI: 10.1007/s40259-015-0126-5

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  3 in total

Review 1.  Analysis of In Vitro Aptamer Selection Parameters.

Authors:  Maureen McKeague; Erin M McConnell; Jose Cruz-Toledo; Elyse D Bernard; Amanda Pach; Emily Mastronardi; Xueru Zhang; Michael Beking; Tariq Francis; Amanda Giamberardino; Ashley Cabecinha; Annamaria Ruscito; Rocio Aranda-Rodriguez; Michel Dumontier; Maria C DeRosa
Journal:  J Mol Evol       Date:  2015-11-03       Impact factor: 2.395

Review 2.  Microfluidic methods for aptamer selection and characterization.

Authors:  Sean K Dembowski; Michael T Bowser
Journal:  Analyst       Date:  2017-12-18       Impact factor: 4.616

3.  High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.

Authors:  Mayumi Takahashi; Xiwei Wu; Michelle Ho; Pritsana Chomchan; John J Rossi; John C Burnett; Jiehua Zhou
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.